Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis

PURPOSE: The aim of this study was to investigate the oncologic efficacy of combining docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen (NSAA) with ADT in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with focus on the effect of seque...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagisawa, Takafumi, Kimura, Takahiro, Hata, Kenichi, Narita, Shintaro, Hatakeyama, Shingo, Mori, Keiichiro, Sano, Takayuki, Otsuka, Takashi, Iwamoto, Yuya, Enei, Yuki, Nakazono, Minoru, Sakanaka, Keigo, Iwatani, Kosuke, Matsukawa, Akihiro, Atsuta, Mahito, Nishikawa, Hideomi, Tsuzuki, Shunsuke, Miki, Jun, Habuchi, Tomonori, Ohyama, Chikara, Shariat, Shahrokh F., Egawa, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Topic Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415473/
https://www.ncbi.nlm.nih.gov/pubmed/35596809
http://dx.doi.org/10.1007/s00345-022-04030-2
Descripción
Sumario:PURPOSE: The aim of this study was to investigate the oncologic efficacy of combining docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen (NSAA) with ADT in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with focus on the effect of sequential therapy in a real-world clinical practice setting. METHODS: The records of 382 patients who harbored high-volume mHSPC, based on the CHAARTED criteria, and had received ADT with either docetaxel (n = 92) or NSAA (bicalutamide) (n = 290) were retrospectively analyzed. The cohorts were matched by one-to-one propensity scores based on patient demographics. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), and time to second-line progression (PFS2) were compared. 2nd-line PFS defined as the time from CRPC diagnosis to progression after second-line therapy was also compared. RESULTS: After matching, a total of 170 patients were retained: 85 patients treated with docetaxel + ADT and 85 patients treated with NSAA + ADT. The median OS and CSS for docetaxel + ADT versus NSAA + ADT were not reached (NR) vs. 49 months (p = 0.02) and NR vs. 55 months (p = 0.02), respectively. Median time to CRPC and PFS2 in patients treated with docetaxel + ADT was significantly longer compared to those treated with NSAA (22 vs. 12 months; p = 0.003 and, NR vs. 28 months; p < 0.001, respectively). There was no significant difference in 2nd-line PFS between the two groups. CONCLUSIONS: Our analysis suggested that ADT with docetaxel significantly prolonged OS and CSS owing to a better time to CRPC and PFS2 in comparison to NSAA + ADT in high-volume mHSPC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-04030-2.

Ejemplares similares